Literature DB >> 20130393

Novel markers of left ventricular hypertrophy in uremia.

Hironori Nakamura1, Masanori Tokumoto, Masahide Mizobuchi, Cynthia S Ritter, Jane L Finch, Masanori Mukai, Eduardo Slatopolsky.   

Abstract

AIMS: Left ventricular hypertrophy (LVH) is the most frequent cardiac complication in chronic renal disease. Previous studies implicate elevated serum phosphorus as a risk factor for LVH.
METHODS: We treated 5/6 nephrectomized rats with enalapril or enalapril + sevelamer carbonate for 4 months to determine if sevelamer carbonate had an additional beneficial effect on the development of LVH and uremia-induced left ventricle (LV) remodeling.
RESULTS: Uremia increased LV weight and cardiomyocyte size. Enalapril and enalapril + sevelamer blunted the increase in left ventricular weight. Only enalapril + sevelamer diminished the increase in cardiomyocyte size. Uremia increased cyclin D2 and PCNA and decreased p27 protein expression in the heart. Enalapril + sevelamer diminished the decrease in p27 expression caused by uremia. Uremia increased Ki67-positive and phosphohistone H(3)-positive interstitial cells. This was not seen in cardiomyocytes. Multivariable regression analysis showed that increased phosphorus was an independent risk factor for both increased LV weight and cardiomyocyte size.
CONCLUSIONS: These data suggest left ventricular remodeling consists of cardiomyocyte hypertrophy and interstitial cell proliferation, but not cardiomyocyte proliferation. p27 and cyclin D2 may play important roles in the development of LVH. In addition, phosphorus can be an independent risk factor for the development of LVH. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20130393      PMCID: PMC2924237          DOI: 10.1159/000279768

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  58 in total

Review 1.  Regulation of cardiac hypertrophy by intracellular signalling pathways.

Authors:  Joerg Heineke; Jeffery D Molkentin
Journal:  Nat Rev Mol Cell Biol       Date:  2006-08       Impact factor: 94.444

2.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

3.  Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.

Authors:  I Reynisdóttir; K Polyak; A Iavarone; J Massagué
Journal:  Genes Dev       Date:  1995-08-01       Impact factor: 11.361

4.  Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes.

Authors:  M Smogorzewski; M Zayed; Y B Zhang; J Roe; S G Massry
Journal:  Am J Physiol       Date:  1993-06

5.  A cell cycle-regulated inhibitor of cyclin-dependent kinases.

Authors:  L Hengst; V Dulic; J M Slingerland; E Lees; S I Reed
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

6.  Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin.

Authors:  J Nourse; E Firpo; W M Flanagan; S Coats; K Polyak; M H Lee; J Massague; G R Crabtree; J M Roberts
Journal:  Nature       Date:  1994-12-08       Impact factor: 49.962

7.  Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction.

Authors:  P G Volders; I E Willems; J P Cleutjens; J W Arends; M G Havenith; M J Daemen
Journal:  J Mol Cell Cardiol       Date:  1993-11       Impact factor: 5.000

8.  Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.

Authors:  R N Foley; P S Parfrey; J D Harnett; G M Kent; C J Martin; D C Murray; P E Barre
Journal:  Kidney Int       Date:  1995-01       Impact factor: 10.612

9.  End-stage cardiac failure in humans is coupled with the induction of proliferating cell nuclear antigen and nuclear mitotic division in ventricular myocytes.

Authors:  F Quaini; E Cigola; C Lagrasta; G Saccani; E Quaini; C Rossi; G Olivetti; P Anversa
Journal:  Circ Res       Date:  1994-12       Impact factor: 17.367

10.  Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation.

Authors:  J Y Kato; M Matsuoka; K Polyak; J Massagué; C J Sherr
Journal:  Cell       Date:  1994-11-04       Impact factor: 41.582

View more
  5 in total

1.  Adiponectin expression and the cardioprotective role of the vitamin D receptor activator paricalcitol and the angiotensin converting enzyme inhibitor enalapril in ApoE-deficient mice.

Authors:  Edu Suarez-Martinez; Kazim Husain; Leon Ferder
Journal:  Ther Adv Cardiovasc Dis       Date:  2014-07-18

2.  Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.

Authors:  Chu Zhou; Fang Wang; Jin-Wei Wang; Lu-Xia Zhang; Ming-Hui Zhao
Journal:  Chin Med J (Engl)       Date:  2016-10-05       Impact factor: 2.628

3.  Assessment of the left ventricular function in patients with uremia using layer-specific 2-dimensional speckle tracking echocardiography.

Authors:  Mengyao Sun; Yu Dong; Ying Wang; Guangsen Li; Dongmei Huang
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

4.  Cardiac and renal effects of atrasentan in combination with enalapril and paricalcitol in uremic rats.

Authors:  Cynthia Ritter; Sarah Zhang; Jane L Finch; Helen Liapis; Edu Suarez; Leon Ferder; James Delmez; Eduardo Slatopolsky
Journal:  Kidney Blood Press Res       Date:  2014-09-19       Impact factor: 2.687

5.  Identification and analysis of a key long non-coding RNAs (lncRNAs)-associated module reveal functional lncRNAs in cardiac hypertrophy.

Authors:  Jian Zhang; Chenchen Feng; Chao Song; Bo Ai; Xuefeng Bai; Yuejuan Liu; Xuecang Li; Jianmei Zhao; Shengshu Shi; Xin Chen; Xiaojie Su; Chunquan Li
Journal:  J Cell Mol Med       Date:  2017-11-20       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.